학술논문
The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients
Document Type
article
Author
Nicole V. Tolan; Amy C. Sherman; Guohai Zhou; Katherine G. Nabel; Michaël Desjardins; Stacy Melanson; Sanjat Kanjilal; Serina Moheed; John Kupelian; Richard M. Kaufman; Edward T. Ryan; Regina C. LaRocque; John A. Branda; Anand S. Dighe; Jonathan Abraham; Lindsey R. Baden; Richelle C. Charles; Sarah E. Turbett
Source
Microbiology Spectrum, Vol 10, Iss 2 (2022)
Subject
Language
English
ISSN
2165-0497
Abstract
ABSTRACT The use of anti-spike (S) serologic assays as surrogate measurements of SARS-CoV-2 vaccine induced immunity will be an important clinical and epidemiological tool. The characteristics of a commercially available anti-S antibody assay (Roche Elecsys anti-SARS-CoV-2 S) were evaluated in a cohort of vaccine recipients. Levels were correlated with pseudotype neutralizing antibodies (NAb) across SARS-CoV-2 variants. We recruited adults receiving a two-dose series of mRNA-1273 or BNT162b2 and collected serum at scheduled intervals up to 8 months post-first vaccination. Anti-S and NAb levels were measured, and correlation was evaluated by (i) vaccine type and (ii) SARS-CoV-2 variant (wild-type, Alpha, Beta, Gamma, and three constructs Day 146*, Day 152*, and RBM-2). Forty-six mRNA vaccine recipients were enrolled. mRNA-1273 vaccine recipients had higher peak anti-S and NAb levels compared with BNT162b2 (P